Structure Therapeutics

Historical price data

Structure Therapeutics is pioneering the development of next-generation oral small molecule medicines targeting G protein-coupled receptors (GPCRs), a historically challenging but highly validated class of drug targets. The company's lead asset, GSBR-1290, is a highly selective oral GLP-1 receptor agonist in Phase 2 development for obesity and type 2 diabetes, aiming to compete with injectable GLP-1 therapies. With a strong pipeline of preclinical candidates for other cardiometabolic and pulmonary conditions, Structure is positioned at the forefront of the oral incretin market. The company's strategy is built on its integrated computational and experimental platform to design differentiated therapeutics with improved patient convenience and adherence.

An integrated structure-based drug discovery platform combining computational modeling, cryo-electron microscopy (cryo-EM), and machine learning to design oral small molecule therapeutics targeting G protein-coupled receptors (GPCRs).

7 drugs in pipeline

Total raised: $368.2M

Main competitors in the oral GLP-1 space include Novo Nordisk (oral semaglutide), Pfizer (danuglipron), and Viking Therapeutics (VK2735). Structure aims to differentiate through its highly selective small molecule design, which may offer pharmacological and manufacturing advantages over peptide-based oral candidates.